Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Erik Lundgren
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 100
- Beta
- 1.41
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -4.88
Financials
Net Income
$-34.10MEBITDA
$-34.00MFree Cash Flow
$-31.25MEPS (diluted)
$-0.80Shares Outstanding (diluted)
42.51M+5273.7%Operating Expenses
$35.33MCash & Debt
$155.10MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-97.17M | $-6.24 |
| 2024 | $0.00 | $-100.51M | $-10.03 |
| 2023 | $0.00 | $-93.61M | $-21.12 |
| 2022 | $0.00 | $-120.41M | $-37.84 |
| 2021 | $0.00 | $-92.94M | $-39.30 |
| 2020 | $0.00 | $-44.02M | $-28.10 |
| 2019 | $0.00 | $-34.83M | $-45.24 |
| 2018 | $0.00 | $-41.48M | $-136.28 |
| 2017 | $0.00 | $-52.08M | $-524.00 |
| 2016 | $6.3K | $-40.97M | $-524.00 |
| 2015 | $0.00 | $-52.02M | $-828.00 |
| 2014 | $0.00 | $-47.67M | $-1416.00 |
| 2013 | $0.00 | $-32.72M | $-528.14 |
| 2012 | $0.00 | $-6.70M | $-128.50 |
Valuation
IMUXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
150+200.00%Social Signal Score
Mentions (7)
- Newsproactiveinvestors.com·34d ago·Neutral
Immunic to host virtual relapsing MS R&D Day on September 9 Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced that it will host a virtual research and development day focused on relapsing multiple sclerosis on September 9, as the biotechnology company prepares for topline results from its Phase 3 ENSURE trials expected by the end of 2026. The event will feature Immunic management, including CEO Erik Lundgren, chief medical officer Michael Panzara, chief scientific officer Hella Kohlhof and president…
View source ↗ - Newsprnewswire.com·34d ago·Neutral
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a virtual research and development (R&D) day focused on relapsing multiple sclerosis (MS) on Wednesday, September 9, 2026, at 11:00 am ET.
View source ↗ - Newsprnewswire.com·35d ago·Neutral
… Commercial-Ready Data Ecosystem, in Preparation for Potential NDA Submission and Commercialization – NEW YORK, Sept. 1, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Chitrang Davé as Chief Data and Digital Officer (CDDO), effective today.
View source ↗ - Newsseekingalpha.com·41d ago·Neutral
Immunic: Potent Under-The-Radar MS Lineup Set For A Rerating Immunic is advancing vidofludimus calcium (IMU-838) in late-stage trials for both relapsing and progressive multiple sclerosis. MS represents a substantial market, with existing therapies projected to reach ~$22 billion in 2026 revenues. IMU-838's oral administration and differentiated mechanism of action position it as a potential major player in the MS market.
View source ↗ - Newsproactiveinvestors.com·56d ago·Negative
Immunic advances MS drug toward key Phase 3 data, expects results by year-end Immunic Inc (NASDAQ:IMUX, FRA:10VA) is preparing for a series of clinical and corporate milestones as it advances its lead drug candidate vidofludimus calcium through late-stage development in multiple sclerosis, while expanding its leadership team ahead of potential regulatory filings and commercialization. The biotechnology company reported second-quarter results on Tuesday and said its Phase 3 ENSURE-1 and ENSURE-2
View source ↗ - Newsprnewswire.com·56d ago·Neutral
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update – Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness – – Pivotal Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis on Track, with Top-Line Data Expected by End of 2026 – – Continued Preparations for Phase 3 T
View source ↗ - Newsprnewswire.com·56d ago·Neutral
Immunic Appoints Elena Ridloff to Board of Directors – Appointment Strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise as the Company Approaches Pivotal Phase 3 ENSURE Readout in Relapsing Multiple Sclerosis as well as Potential Regulatory Filings and Commercialization – NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today annou
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.94 per share
Typical surprise -33.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.80 vs $-1.16beat
- Wed, May 13$-1.08 vs $-0.71miss
- Thu, Feb 26$-1.20 vs $-0.90miss
- Thu, Nov 13$-1.30 vs $-0.18miss
- Thu, Aug 7$-2.00 vs $-1.58miss
- Thu, May 15$-2.50 vs $-2.50beat
Estimates and results for IMUX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IMUX officers and directors.
- Bought
- $347k
- Sold
- —
8 trades
0 trades
- Nash Duanebought
- Tardio Jasonbought
- Neermann Joergbought
- Vitt Danielbought
- Neermann Joergbought
- Whaley Glennbought
- Rudick Richard Alanbought
- Rudick Richard Alanbought
92 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IMUX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.